Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18890243 | 1.00 | GLS (1.00) | GLS | |
| SCHEMBL18890242 | 1.00 | GLS (1.00) | GLS | |
| SCHEMBL18890248 | 0.93 | GLS (1.00) | GLS | |
| SCHEMBL18890244 | 0.93 | GLS (1.00) | GLS | |
| SCHEMBL18890246 | 0.93 | GLS (1.00) | GLS | |
| SCHEMBL18890236 | 0.93 | GLS (1.00) | GLS | |
| SCHEMBL21952111 | 0.92 | GLS (1.00) | GLS | |
| SCHEMBL18890238 | 0.92 | GLS (1.00) | GLS | |
| SCHEMBL18890237 | 0.92 | GLS (1.00) | GLS | |
| SCHEMBL29017174 | 0.85 | GLS (0.74) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349951-B | Bispyridazine compound | 阿斯利康(瑞典)有限公司 | 2020-11-13 | — | — | CN | claimed |
| CN-108349951-B | Bispyridazine compound | 阿斯利康(瑞典)有限公司 | 2020-11-13 | — | — | CN | disclosed |
| US-10577354-B2 | Bis-pyridazine compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| US-20190169172-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577354-B2 | Bis-pyridazine compounds and their use in treating cancer | GLS2, GLS, GLUL | GLS 2/4885 |
| US-20190169172-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | GLS2, GLS, GLUL | GLS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.